LUCD (Lucid Diagnostics) Net Change in Cash: $2.28 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LUCD Lucid Diagnostics Inc LUCD
16 GF Score
Price $0.88
GF Value $0.73
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lucid Diagnostics Net Change in Cash?

Lucid Diagnostics LUCD -1.62% 16 Net Change in Cash is $2.28 Mil as of Jun. 2026. GuruFocus rates LUCD with a GF Score™ of 16/100 and a GF Value™ of $0.73 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Lucid Diagnostics's Net Change in Cash for the three months ended in Jun. 2026 was $5.53 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2026 was $2.28 Mil.

Lucid Diagnostics Net Change in Cash Historical Data

* Premium members only.

The historical data trend for Lucid Diagnostics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lucid Diagnostics Net Change in Cash Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Change in Cash
Get a 7-Day Free Trial 53.55 -31.18 -3.58 3.46 12.35

Lucid Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.89 16.21 -12.63 -6.83 5.53
LUCD
16GF Score
Lucid Diagnostics Inc LUCD
Net Change in Cash is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lucid Diagnostics Net Change in Cash Calculation

Lucid Diagnostics's Net Change in Cash for the fiscal year that ended in Dec. 2025 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-46.485+-0.197+59.029+0
=12.35

Lucid Diagnostics's Net Change in Cash for the quarter that ended in Jun. 2026

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-11.297+-0.021+16.846+0
=5.53

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Change in Cash →
What does a Net Change in Cash of $2.28 Mil mean?
Lucid Diagnostics (LUCD) has a Net Change in Cash of $2.28 Mil as of Jun. 2026. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Lucid Diagnostics and its competitors.
Is Lucid Diagnostics' Net Change in Cash too high?
Lucid Diagnostics' current Net Change in Cash is $2.28 Mil. Overall, Lucid Diagnostics has a GF Score™ of 16/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Net Change in Cash compare to QSI and STIM?
Lucid Diagnostics' Net Change in Cash of $2.28 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Change in Cash for a Medical Devices & Instruments company?
A good Net Change in Cash depends on the Medical Devices & Instruments industry context. However, Net Change in Cash should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Change in Cash mean?
A high Net Change in Cash can signal that a stock is expensive relative to its fundamentals. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Lucid Diagnostics and its competitors. Lucid Diagnostics's current Net Change in Cash is $2.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.73, compared to a current price of $0.88 — trading 20.9% above its estimated fair value. The current Net Change in Cash is $2.28 Mil. Lucid Diagnostics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Change in Cash calculated?
Net Change in Cash is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Net Change in Cash is $2.28 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lucid Diagnostics (LUCD) Overvalued in 2026?

Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued. The current stock price of $0.88 is trading 20.9% above its estimated GF Value™ of $0.73. GuruFocus considers Lucid Diagnostics to be Modestly Overvalued.

Key valuation signals for LUCD:

  • Net Change in Cash: $2.28 Mil
  • GF Value™: $0.73 vs. price of $0.88 (20.9% above fair value)
  • GF Score™: 16/100 with 5 warning signs

No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lucid Diagnostics Business Description

Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
16GF Score

Get the complete analysis for LUCD

Net Change in Cash is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.88
Price
$0.73
GF Value